Xiaolei Shi

Has grant

Assistant professor

University of Maryland Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Advancing Oncologic Research Communities in Health Equity (ARCH) K12 Career Development Award

Open Date: 2026-09-01

Close Date: 2028-08-01

Grant: Close

Cancer Biology T32 Training Grant

Open Date: 2024-07-01

Close Date: 2026-06-01

Articles (13)

Year:

2026

Year:

2026

Year:

2026

Purpose of review Genomic and transcriptomic sequencing technologies have revolutionized our ability to characterize prostate cancer at the molecular level. The underlying premise of next-generation sequencing technologies and their current and evolving applications in prostate cancer management are provided in the review. Recent findings Improved methodologies are allowing timely sequencing of the coding regions or both the coding and noncoding regions of the genome to help identify potential mutations and structural variations in the prostate cancer genome, some of which are currently also targetable therapeutically. DNA microarray- based differential gene expression has been supplanted by RNA sequencing (RNA-seq), which not only allows for more accurate quantitation but also nucleotide-level resolution to investigate the entire transcriptome, including alternative gene spliced transcripts and noncoding RNA transcripts, whose full clinical implications have yet to be fully understood and realized. Gene classifier platforms that predict risk of recurrence or metastasis are being incorporated into prostate cancer management algorithms. In the appropriate clinical context, not only somatic but also germline mutation testing is being recommended. Summary Continued clinical integration of sequencing technologies and ongoing research will lead to improved understanding of prostate cancer biology and prostate cancer treatment.

Year:

2025

Purpose of review In the era of precision medicine, the introduction of FDA-approved prostate-specific membrane antigen (PSMA) targeting tracers has revolutionized prostate cancer imaging. These tracers enable functional positron emission tomography (PET) imaging, allowing for precise identification of the location and extent of prostate cancer spread. This review serves as a practical guide for multidisciplinary teams caring for prostate cancer patients, outlining the current approved uses of PET imaging with PSMA tracers and exploring its future applications. Recent findings PSMA PET/CT has become a reliable modality for initial staging in patients with intermediate-to-high risk prostate cancer, restaging in cases of biochemical recurrence and further clarifying disease status among patients with conventional imaging based nonmetastatic castrate resistant prostate cancer and metastatic prostate cancer. Additionally, it has promising roles in selecting patients for radioligand therapy, monitoring treatment response, and guiding therapeutic decision-making. Summary PSMA PET/CT is currently a crucial imaging tool used at key stages of prostate cancer management, with ongoing research exploring its potential for additional clinical applications.

Year:

2025

Year:

2025

Comparison of the frequencies of additional molecular features between non-castrate (NC) and castrate (C) samples in ATMm, BRCA2m, HRDother, and HRP groups. The significant differences between the two groups are highlighted (red box).

Year:

2025

Acetate is an important metabolite in metabolic fluxes. Its presence in biological entities originates from both exogenous inputs and endogenous metabolism. Because the change in blood acetate level has been associated with both beneficial and adverse health outcomes, blood acetate analysis has been used to monitor the systemic status of acetate turnover. The present study examined the use of urinary N-acetyltaurine (NAT) as a marker to reflect the hyperacetatemic status of mice from exogenous inputs and endogenous metabolism, including triacetin dosing, ethanol dosing, and streptozotocin-induced diabetes. The results showed that triacetin dosing increased serum acetate and urinary NAT but not other N-acetylated amino acids in urine. The co-occurrences of increased serum acetate and elevated urinary NAT were also observed in both ethanol dosing and streptozotocin-induced diabetes. Furthermore, the renal cortex was determined as an active site for NAT synthesis. Overall, urinary NAT behaved as an effective marker of hyperacetatemia in three experimental mouse models, warranting further investigation into its application in humans.

Year:

2024

Purpose: In metastatic prostate cancer (mPC) patients, ATM and BRCA2 mutations dictate differences in PARP inhibitor response and other therapies. We interrogated the molecular features of ATM- and BRCA2- mutated mPC to explain the divergent clinical outcomes and inform future treatment decisions. Experimental design: We examined a novel set of 1187 mPCs after excluding microsatellite unstable (MSI) tumors. We stratified these based on ATM (n = 88) or BRCA2 (n = 98) mutations. As control groups, mPCs with mutations in 12 other HRR genes were considered non- BRCA2/ATM HRR-deficient (HRDother, n = 193), whereas lack of any HRR mutations were considered HRR-proficient (HRP) (n = 808). Gene expression analyses were performed using Limma. Real-world overall survival was determined from insurance claims data. Results: In non-castrate mPCs, only BRCA2 mutated mPCs exhibited worse clinical outcomes to AR-targeted therapies. In castrate mPCs, both ATM and BRCA2 mutations exhibited worse clinical outcomes to AR-targeted therapies. ATM -mutated mPCs had reduced TP53 mutations, and harbored co-amplification of 11q13 genes including CCND1 and genes in the FGF family. BRCA2- mutated tumors showed elevated genomic loss-of-heterozygosity scores and were often TMB-high. BRCA2 -mutated mPCs had upregulation of cell cycle genes and were enriched in cell cycle signaling programs. This was distinct from ATM- mutated tumors. Conclusions: Tumoral ATM and BRCA2 mutations are associated with differential clinical outcomes when patients are stratified by treatments including hormonal or taxanes therapies. ATM- and BRCA2- mutated tumors exhibited differences in co-occurring molecular features. These unique molecular features may inform therapeutic decisions and development of novel therapies.

Year:

2024

Comparison of the frequencies of additional molecular features between non-castrate (NC) and castrate (C) samples in ATMm, BRCA2m, HRDother, and HRP groups. The significant differences between the two groups are highlighted (red box).

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (15)

Ryan Park

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

John Lozada

University of Rochester Medical Center

UNITED STATES
View details

Benedito A. Carneiro

-

UNITED STATES
View details

Philippa Kennedy

Faculty, Assistant Professor

University of Minnesota

UNITED STATES
View details

Emil Lou

University of Minnesota

UNITED STATES
View details

Eugene Shenderov

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Kent Mouw

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Justin Hwang

Associate Professor

University of Minnesota

UNITED STATES
View details

Jinhua Wang

professor

University of Minnesota System

UNITED STATES
View details

Elisabeth I. Heath

Wayne State University School of Medicine

UNITED STATES
View details

Emmanuel S. Antonarakis

-

UNITED STATES
View details

Ana Aparicio

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sumit Subudhi

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nicholas Zorko

Assistant Professor

University of Minnesota

UNITED STATES
View details

Rana R. McKay

University of California, San Diego

UNITED STATES
View details